Core Viewpoint - Aikang Medical (01789) has announced a share buyback plan of up to HKD 150 million, which has positively impacted its stock price, leading to a rise of over 4% [1] Group 1: Share Buyback Announcement - On February 2, Aikang Medical announced that the board plans to utilize the share buyback authorization and may use up to HKD 150 million in the open market, depending on market conditions [1] - The company intends to fund the share buyback using its internal financial resources and plans to cancel all repurchased shares after settlement according to applicable rules and regulations [1] Group 2: Product Development and Market Position - Aikang Medical's subsidiary, Yidian Lingdong, has received NMPA approval for a Class III medical device registration certificate for a joint replacement surgery navigation system, marking the launch of its first full joint surgical robot [1] - The company has deployed nearly 100 joint robot products in the market, creating effective synergy between joint robots and its existing prosthetic business [1] - Multiple joint robots are expected to be awarded contracts in 2026, establishing a closed-loop from medical engineering integration to clinical application [1]